Uscom 4C Quarterly Results Q2 FY22
Uscom 4C Q2 FY22
Cash Flow
The Uscom 4C for Q2 FY22 reports total cash receipts of $1.31m, up 79% from $0.73m in Q1 FY22, and
receipts from customers increased 54% from $0.53m to $0.81m. Net operating cash flow for the
quarter was -$0.04m improved from -$0.21m in Q1. Cash on hand at the end of the quarter was
$5.54m, including $4.3m from the non-renounceable rights issue, and being an estimated 145.7
quarters of available cash assuming no growth in operating cash flow or additional capital investment.
Revenue
Sales for Q1 and Q2 FY22 have been impacted by the global Omicron COVID pandemic limiting access
to hospitals and their purchasing systems. Normal sales are anticipated to resume as the pandemic
resolves and normal hospital business recovers. Sales for Q3 are showing improvement but results will
depend on the rate of pandemic recovery and the absence of a successive COVID variant or new
widespread infectious pathogens.
Expenditure
Expenditure for the quarter was predominantly on staff costs ($0.66m), administration and corporate
costs ($0.45m) and advertising and marketing expenses ($0.16m).
The amount included in line 6.1 of appendix 4C is the payment of fees to Directors.
Uscom Executive Chairman, Professor Rob Phillips said “Uscom is in a strong cash position coming into 2022 as it prepares to implement a number of global strategic growth initiatives. We have $5.54m cash on hand while our net operating Q2 cash flow was only fractionally negative, -$0.04m, despite the challenges of the global pandemic. Concurrently Uscom management are actively advancing identified strategies to incrementally grow the business as the pandemic recedes, and continuing discussions with potential international manufacturing and strategic partners.”